

---

## SECONDARY HYPERTRIGLYCERIDEMIA

**Irwin Benuck, MD, PhD**, Community Based General Pediatrics. Northwestern University Feinberg School of Medicine. 225 East Chicago Avenue, Box 162, Chicago, Illinois 60611-2605. [IBenuck@luriechildrens.org](mailto:IBenuck@luriechildrens.org)

**Don P. Wilson MD**, Department of Pediatrics, Pediatric Endocrinology and Diabetes, Cook Children's Medical Center, 1500 Cooper St Floor 2, Fort Worth, TX 76104. [Don.Wilson@cookchildrens.org](mailto:Don.Wilson@cookchildrens.org)

**Catherine McNeal, MD, PhD**, Department of Internal Medicine, Division of Cardiology, Scott & White Healthcare, 2401 S. 31st St., Temple TX 76508. [Catherine.McNeal@BSWHealth.org](mailto:Catherine.McNeal@BSWHealth.org)

**Updated May 1, 2023**

### ABSTRACT

Hypertriglyceridemia (HTG) is often secondary to obesity-related insulin resistance (1,2), which is caused by excessive intake of fats and carbohydrates without compensatory utilization of these calories, but other common and rare causes should be considered (3,4,5). Genetic influences, gestational conditions, and nutrition in infancy and childhood contribute to HTG associated with formation of an atherogenic dyslipidemia profile consisting of high TG, low high-density lipoprotein-cholesterol (HDL-C), increased LDL particle number, smaller LDL size and density, and elevated apolipoprotein B. Very high TG levels generally result from defective disposal by lipoprotein lipase and can cause pancreatitis. Defining and treating the underlying cause are necessary to restore the lipids and lipoproteins to normal. Renal, hepatic, endocrine, immune, and pharmacological causes are in the differential diagnosis. Rare diseases such as lipodystrophy and glycogen storage disease are particularly challenging and require specific management strategies. Prevention of acute pancreatitis by lowering TG is a priority when TG is very high (> 1000 mg/dl), and lifestyle modification is the basis of management for all cases with high and

moderately high levels. Since TG metabolism is associated with generation of an atherogenic dyslipidemia profile, predictors of coronary artery disease (CAD) such as LDL-C and non-HDL-C become targets when they exceed cut points.

### INTRODUCTION

This chapter is an overview of causes of hypertriglyceridemia (HTG) that begin during gestation and present in childhood and adolescence, either interacting with genetic background or directly contributing to the TG levels. These disorders are common, such as obesity, or less common such as glycogen storage disease and lipodystrophy for which treatment can be more challenging. Also, both common and unique pharmaceutical agents need to be considered as causes since treatment modification can contribute to reversing the HTG. Dyslipidemia presenting in adolescence is often associated with one or more components of the metabolic syndrome, i.e., obesity, hypertension, and impaired glucose tolerance, and presents with high TG and low HDL-C (6,7,8, 9,10) however, a wide variety of other causes can contribute to the differential diagnosis of HTG.

---

Genetic background, gestational factors, nutrition during infancy and childhood, demographic, and environmental factors are important considerations. Also, understanding how TG is distributed among lipoproteins and how it influences lipoprotein composition and subsequent lipolysis, uptake by receptors and the arterial wall provides important background for understanding associations with specific diagnoses and when treatment can be effective.

## DIET

Although the Cardiovascular Health Integrated Lifestyle Diet (CHILD 1) (11) recommends a balanced diet of carbohydrates (50%), which includes fiber, fat (30%) of which no more than 10% of total calories come from saturated fats, and protein (20%), these guidelines are often not well adhered to. Nutritional intake by many individuals comprises additional consumption of nonessential calories consisting of fats, both saturated and trans fats, as well as carbohydrates such as High-Energy Fructose Corn Syrup (HFCS) and sucrose. This coupled with a decrease in physical activity and increased time spent in leisure activities (i.e., screen time) leads to excessive weight gain, often starting at a young age, metabolic syndrome, and insulin resistance. In an active pediatric preventive cardiology program, the number of children referred because of secondary hypertriglyceridemia and obesity is approximately twice that of children referred for Familial Hypercholesterolemia (12). As excessive consumption of fat and sugar will result in increased levels of triglycerides, it is important to understand both these metabolic pathways and nutritional management is the first step in any treatment algorithm (13).

Because of the 2011 NHLBI recommendations for universal screening between 9 and 11 years of age,

pediatric medical providers are encouraged to evaluate patients at this time with a non-fasting non-HDL cholesterol (14). However, children with additional risk factors notably including a BMI >95<sup>th</sup> %ile, should be screened with a fasting lipid profile as early as 2 years of age. Other children in this category include those whose parent or grandparent have a known history of a cardiac event such as myocardial infarction (mother or grandmother <65 years of age; father or grandfather <55 years of age), children with diabetes or hypertension.

Dietary consumption of HFCS has increased rapidly since its discovery in 1965 (15). It is a low-cost sweetener, similar in taste to granulated sugar (sucrose), made from cornstarch and is commonly used in two forms. The first form HFCS is widely used commercially in some beverages, processed foods, cereals, and baked goods; the second HFCS is used in manufacturing of soft drinks (the numerical values reflect the percent fructose) (16). Although there is some dispute whether HFCS has led to the increase in obesity (17), it is apparent that both forms are consumed in larger quantity in the American diet. In 2018, the average American consumed approximately 22.1 pounds of HFCS and 40.3 pounds of refined cane and beet sugar (18).

Both sucrose and HFCS are rapidly absorbed during digestion and hydrolyzed by the enzyme sucrase to form glucose and fructose in the microvilli lining the duodenum (19). Unlike fat metabolism which is slow, both fructose and glucose are usually metabolized within two hours in individuals who are not diabetic (20). Whereas most dietary glucose will pass through the liver and be used by skeletal muscle to form ATP for cell energy or processed by fat cells to glycerol phosphate for triglyceride synthesis and stored energy, fructose is almost exclusively metabolized in the liver (Figure 1). The first step of fructose

metabolism is the conversion to fructose 1-phosphate (F-1-P) by the enzyme fructokinase. F-1-P can then form either glycerol or dihydroxyacetone (DHAP). Whereas glycerol will form glycerol-3 Phosphate (G3P), DHAP can either form G3P or be isomerized to glyceraldehyde 3-phosphate (Ga-3-P). Ga-3-P will be oxidized to form pyruvate and reduced to lactate or be decarboxylated to form acetyl CoA. Acetyl CoA is a central intermediate in metabolism and can form a variety of byproducts including cholesterol, ATP, and

fatty acids. G3P can then combine with fatty acids to form triglyceride which the liver packages as VLDL, the latter circulated in the blood stream. Hepatic glucose can either undergo glycogenesis which forms glycogen or glycolysis which can form DHAP. Like fructose metabolism, DHAP can form either G3P or Ga-3-P. From here the two pathways are similar to fructose metabolism with the ultimate formation of triglyceride which is then released from the liver within VLDL.




Figure 1. Fructose and Glucose Metabolism.

## TG-RICH LIPOPROTEIN COMPOSITION

Triglyceride (TG) is normally located in the core of spherical circulating plasma lipoproteins. In the fasting state, VLDL is typically composed of 55% TG and 22% cholesterol, LDL has 5% TG and 50% cholesterol, and HDL has 5% TG and 20% cholesterol (21). Increases in hepatic

production of VLDL account for the majority of HTG cases resulting in a disproportionate increase in TG. However, VLDL is 22% cholesterol, which also is increased when VLDL production is excessive or when its disposal is defective leading to an elevation of the total cholesterol. In contrast, intestinally derived chylomicrons increase after meals and contain 90% triglyceride and only 3% cholesterol, but are efficiently catabolized by lipoprotein lipase, and their resulting remnant particles are taken up by hepatic receptors. Normally, TG reaches a peak 3 to 6 hours after a fat-containing meal and declines until there are no chylomicrons after ten hours of fasting. However, when disposal mechanisms are defective, chylomicrons account for very high TG levels and VLDL particles compete for lipolysis by lipoprotein lipase. Under these conditions the ratio of triglyceride to cholesterol approaches 10 to 1, whereas the ratio is closer to 5 to 1 when VLDL predominates. Excessive cholesterol enrichment of VLDL approaching a 1:1 ratio occurs when disposal of chylomicron and VLDL remnants are delayed – a defect usually presenting in adulthood and termed familial dysbetalipoproteinemia, a disorder attributed to variation in the amino acid sequence of Apo E (22).


## NON-HDL CHOLESTEROL IN HTG

Since increased TG levels are often associated with atherogenic dyslipidemia, early plaque formation can occur. The Bogalusa Heart Study found that TG, total cholesterol and LDL-C in children and young adults aged 2 to 39 years of age were associated with post-mortem lesions in the coronary arteries and aorta (23), findings supported by the autopsy-based Pathological Determinants of Atherosclerosis in Youth (PDAY) study (24). While HTG has long been known as a biomarker associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD) (25), the role for TG in atherosclerosis has remained less clear than for LDL-C but recent data supports a compelling role for TG and TG-rich lipoproteins as a cause of ASCVD rather simply as a biomarker (26,27,28). Consistently stronger prediction by non-HDL-C than LDL-C indicates that the cholesterol content of TG-rich lipoproteins (VLDL, IDL) represented by non-HDL-C can be regarded as a better predictor of risk than TG. This is also supported by the PDAY study in which non-HDL-C was associated with fatty streaks and raised lesions (29), and risk factors, including non-HDL-C and low HDL-C, accelerated progression of flat fatty streaks to raised lesions in the second decade. Childhood non-HDL-C, TG, Apo B, and Apo B:Apo A-I ratio all predicted carotid IMT after more than 20 years of follow-up, with non-HDL-C being superior to TG. (30) Therefore, targeting non-HDL-C in cases with intermediate triglyceride levels is a useful and productive strategy endorsed by the 2011 NHLBI (National Heart Lung and Blood Institute) Expert Panel's recommendations (14).

## TG METABOLISM IN THE SETTING OF INSULIN RESISTANCE

Common secondary HTG occurs in insulin resistant states such as obesity and type 2 diabetes (T2D) and

can often become modified or exacerbated by other secondary causes. Since the abnormal lipid metabolism in insulin resistance has been extensively studied it serves as a foundation for understanding secondary dyslipidemia and potential for exacerbation by other causes (Figure 2).



**Figure 2. Lipoprotein Metabolism in Insulin Resistance.** A combination of excess production and disposal processes results in secondary HTG and atherogenic dyslipidemia in the insulin resistant state. Chylomicrons and VLDL production originating from the intestine and liver are increased. Mobilization of free fatty acids (FFA) from fat cells by hormone sensitive and TG lipases (HSL/TGL) provides the liver with substrate for VLDL formation. Dietary intake of fat provides the intestine with TG for chylomicron formation, which is upregulated in insulin resistance. Hepatic VLDL containing excess Apo C-III relative to Apo E is increased; Apo C-III delays receptor-mediated hepatic uptake of VLDL and chylomicron remnants resulting in formation of intermediate density lipoproteins (IDL, not shown) and smaller and denser low-density lipoproteins (LDL). Lipoprotein lipase (LPL) is inhibited by Apo C-III and decreased by insulin resistance and/or deficiency. Cholesterol ester transfer protein (CETP) is upregulated resulting in exchange of TG and cholesterol ester (CE), leading to TG enrichment of LDL and HDL. Both become substrates for hepatic triglyceride lipase (HTGL), which is upregulated and acts on TG-enriched HDL and LDL to make them smaller, atherogenic and dysfunctional. Apolipoproteins A-I, B-48, B-100, C-I, C-II, C-III (C), and E are labelled and play important roles in lipoprotein metabolism.



## HTG PREVALENCE

In the U.S., the latest prevalence data for HTG comes from the 1999 - 2006 NHANES study, which found prevalence rates of 5.9% in normal weight children, 13.8% in overweight children and 24.1% in obese children (31). Given that Skinner et al found a positive linear trend for all definitions of overweight and obesity among children 2-19 years old, most prominently among adolescents and children aged 2 to 5 years (32), the current prevalence of HTG is almost

certainly significantly higher. Abnormal TG levels for children are generally classified on the basis of cut points based on population norms recommended by the American Academy of Pediatrics and the American Heart Association (33). The 50th to 95th percentile values for TG in children are presented in Table 1. Acceptable levels in children defined by the Expert Panel on Integrated Guidelines for Cardiovascular Health (14) are summarized in Table 2.

**Table 1. Triglyceride Levels for Males and Females 5-19 Years of Age**

Percentile	Males			Females		
	5-9 yrs	10-14 yrs	15-19 yrs	5-9 yrs	10-14 yrs	15-19 yrs
50 <sup>th</sup>	48	58	68	57	68	64
75 <sup>th</sup>	58	74	88	74	85	85
90 <sup>th</sup>	70	94	125	103	104	112
95 <sup>th</sup>	85	111	143	120	120	126

Mean concentration of triglycerides (mg/dL). Adapted from: Tamir I, Heiss G, Glueck CJ, Christensen B, Kwiterovich P, Rifkind B. Lipid and lipoprotein distributions in white children ages 6–19 yrs: the Lipid Research Clinics Program Prevalence Study. J Chronic Dis. 1981; 34(1):27– 39.

**Table 2. Acceptable Lipid levels for Children - Expert Panel on Integrated Guidelines for Cardiovascular Health (14)**

	Acceptable	Borderline	High
<b>Total Cholesterol</b>	<170	170-199	≥200
<b>LDL-C</b>	<110	110-129	≥130
<b>Non-HDL-C</b>	< 120		
<b>Triglycerides</b>			
<b>0-9 years</b>	<75	75-99	≥100
<b>10-19 years</b>	<90	90-129	≥130

---

The non-HDL-C which is equally accurate when measured on a fasting or non-fasting lipid panel reflects the sum of all apolipoprotein (Apo)-B-containing, triglyceride-rich lipoprotein subfractions (LDL, VLDL, Intermediate-Density Lipoprotein (IDL), lipoprotein (a), and chylomicron remnants. As triglycerides increase, there is a corresponding increase in the non-HDL-C level which correlates with Apo B much better than LDL-C. Hypertriglyceridemia can be diagnosed if TG level is  $\geq 100$  mg/dL in children ( $<10$  year) or  $\geq 130$  mg/dL in adolescents (10–19 years) based on an average of two fasting measurements. Severe secondary hyper-TG, defined as levels above 1000 mg/dL, presents a risk for acute pancreatitis, especially when lipoprotein lipase-mediated clearance is saturated ( $> 800$  mg/dL) causing the triglyceride to attain very high levels often exceeding 1000 mg/dL, with appearance of chylomicrons on standing plasma. Moderate HTG, defined as levels 150–499 mg/dL, is a risk factor for CVD. These children tend to be undertreated despite potential for reversal and primary prevention of cardiovascular disease (34).

## MEASUREMENT ASPECTS

Although the non-HDL-cholesterol does not require fasting, the standard lipid profile which includes total cholesterol (TC), LDL-C, HDL-C, TG, and very low-density lipoprotein-cholesterol (VLDL-C) should be performed in pediatric patients in the fasting state (at least 8 hours) and guideline directed therapy is based on fasting values. Currently, some laboratories still use a calculated value for VLDL-C and LDL-C based on the Friedewald Formula (35) which estimates the VLDL-C by a fixed ratio of 5 ( $VLDL-C = TG/5$ ). Because of the significant deviation from linearity at high TG levels (typically 400 mg/dL is used as a cut-point), VLDL-C and LDL-C values are not reported. This is especially important in dyslipidemias where

both the TG and LDL-C can be elevated (i.e., familial combined hyperlipidemia) or where the TG level is severely elevated as a result of genetic and/or nutritional factors because it can lead to an under appreciation of the extent of the LDL-C elevation, the latter being especially important for guideline-directed therapy to lower cholesterol and in particular, LDL-C. Recently several equations have been developed that improved the accuracy of the calculated LDL-C. The Martin-Hopkins equation uses an adjustable factor based on lipid profiles from the Very Large Database of Lipids where TG levels were directly measured on samples separated using vertical spin density-gradient ultracentrifugation rather than a fixed ratio to calculate VLDL-C and subsequently the LDL-C (36). While this equation is more accurate than the Friedewald equation at high TG levels, there is still significant error for  $TG > 400$  mg/dL addressed by the extended Martin/Hopkins calculation (37) and the Sampson equation (38). The Sampson equation was derived using beta quantification LDL-C values (the “gold standard” for LDL-C values) using multiple least squares regression analysis to derive a fixed equation to calculate the LDL-C value. All three equations have been proven to be superior to the Friedewald equation and many laboratories have already incorporated these equations when reporting lipid measures. Several pediatric studies have specifically addressed these improved methods to calculate VLDL-C and LDL-C (39,40,41).

## GENETIC BACKGROUND

Commonly encountered HTG is usually multigenic and results from small-effect variants (single nucleotide polymorphisms) in many genes or heterozygotes in genes such as *APOA5*, *GCKR*, *LPL*, and *APOB* that have larger effects and together, more than 20% of susceptibility is accounted for by common and rare variants (42). The population frequency of the HTG

---

phenotype was shown in the Copenhagen General Population Study in which a small percentage have a non-fasting TG level greater than 1000 mg/dL, whereas the majority have intermediate levels ranging from greater than the 95<sup>th</sup> percentile to 500 mg/dL and higher, often secondary to an underlying disorder (43).

### Gene-Environment Interaction

Heterozygous relatives of cases with autosomal recessive familial chylomicronemia carry loss-of-function mutations in genes such as *LPL*, *APOC2*, *APOA5*, *LMF1*, and *GPIHBP* are generally

asymptomatic. Although they have close to normal lipids they may develop severe HTG (44) when exposed to exogenous factors such as alcohol, oral estrogen treatment, obesity, and pregnancy posing a risk for acute pancreatitis (45,46). These observations suggest that adolescent carriers, such as siblings of severely affected homozygotes, should be identified by genotyping to detect carriage of a single allele. If identified as carriers, they should be advised on avoiding risk factors such as alcohol and pharmaceutical agents discussed further in this review.

Susceptibility to environmental factors is common; for example, a typical case scenario occurs in a child with a mild increase in LDL-C who develops an increase in triglyceride and non-HDL-C during adolescence. The HTG is worsened by the onset of obesity and participation in social activities involving alcohol consumption and taking oral estrogens as birth control pills. Since insulin resistance and T2D have become more common in adolescence, the gene-environment interaction results in mixed dyslipidemia (47) with variable elevations in TG and cholesterol (48). The interaction is common in cases with a pedigree suggestive of familial combined hyperlipidemia (FCHL) reported to have a prevalence of 1 per 100 and

characterized by variable lipid profiles among family members with apparent dominant inheritance, but some have a high cholesterol and others have a high triglyceride or elevations in both. The phenotype has also been defined as having elevated Apo B and TG levels in at least two affected family members, and has been associated with several variants including *USF1*, supporting a multigenic rather than a monogenic origin as originally thought (49).

### Mendelian Randomization


The important role of genetics in determining HTG associated risk is highlighted by recent Mendelian randomization studies in which individuals carrying a protective mutation were compared to unaffected carriers over a lifetime. Recent studies on loss of function *APOC3* mutations are a classic example. As compared with non-carriers, carriers of *APOC3* mutations had 39% lower TG levels, 16% lower LDL-C levels, and 22% higher HDL-C levels (50). The risk of coronary heart disease was reduced by 40% and was attributed to the lifetime effect of the normal or low levels. These remarkable findings were replicated in a Danish study with similar reductions in TG and cardiovascular disease in individuals with the protective *APOC3* mutations (51). Randomization occurs in populations when sorted according to genotype and provides study design analogous to that used in pharmaceutical trials, but with the added benefit that exposure to lower levels of atherogenic lipoproteins in the genetically protected arm of the study begins at birth and continue over the lifespan. These landmark studies contribute evidence that a low TG and an associated improved lipid profile is beneficial, and supports interventions such as lifestyle, and pharmaceutical lowering when indicated, beginning at young ages.



## DEVELOPMENTAL FACTORS

A sequence of factors, beginning during gestation,

influence the development of hypertriglyceridemia (HTG) later in life (Figure 3).



**Figure 3. Developmental Influences.** Metabolic processes are programmed during gestation and early childhood and are influenced by disease states and environmental factors such as dietary excess and inactivity. The HTG is associated with atherogenic dyslipidemia consisting of increased non-HDL-C (non-high-density lipoprotein-cholesterol), LDL-P (LDL particle number), Apo B (apolipoprotein B), decreased HDL-C (high density lipoprotein cholesterol) and decreased Apo A-I.

Maternal nutrition and placental function affect nutrient supply for fetal growth and influence subsequent development of the metabolic syndrome (52). Overweight children who were small for gestational age (SGA) have increased risk for components of the metabolic syndrome compared to overweight children who were appropriate for gestational age (AGA). These effects on growth are attributed to restriction in intrauterine growth (53). After gestational programming, nutritional and endocrine factors play a role during childhood and affect development of risk factors including dyslipidemia (Figure 3). Preterm

infants have higher meal frequency than older children and adults, but less efficient fat digestion and absorption, making it difficult to cope with a high fat intake relative to their body weight (54). Consequently, HTG is a frequent occurrence. Since pancreatic lipase and bile salt secretion is often inadequate for facilitating absorption of fat and its utilization as a source of energy, premature babies often fail to thrive and need exogenous fat as a component of total intravenous parenteral nutrition titrated according to the TG level (55). If lipoprotein lipase is genetically defective plasma clearance is even more

compromised and severe HTG occurs during lipid infusions. If clinical circumstances necessitate that fats be restricted, essential omega-3 and omega-6 fatty acids are supplied for development of the brain and retina, and medium chain TG are an effective energy source without raising TG levels since they are directly transported to the liver via the portal system (56).

Increases in obesity, particularly as abdominal fat, during childhood predict the metabolic syndrome and compound the effect of an abnormal birth weight (57). Also, low adiponectin has been associated with insulin resistance, particularly in African American youth and compounds dyslipidemia (58). The adrenal axis may be involved; urinary free cortisol is associated with the metabolic syndrome in children (59), but the role of cortisol is controversial. Conversion of cortisone to cortisol by 11 beta -hydroxysteroid dehydrogenase

type 1 (11 beta -HSD1) results in cortisol excess leading to insulin resistance, hypertension, and dyslipidemia. Inhibition of the enzyme results in reversal of metabolic syndrome criteria providing potential for pharmaceutical intervention (60). Normal puberty causes a transient increase in insulin resistance, attributed to maturational increases in sex and growth hormones, and may increase prevalence of both the metabolic syndrome and type 2 diabetes (61).

## SECONDARY CAUSES OF HYPERTRIGLYCERIDEMIA

While primary HTG is associated with relatively rare monogenic and more common polygenic forms, there are many secondary non-genetic factors. The lipid abnormalities associated with these causes are summarized in Table 3.

**Table 3. Secondary HTG Causes, Lipid Effects and Mechanism**

Disease	TG	Chol	HDL-C	Mechanism
<b>a). HTG (variable hypercholesterolemia)</b>				
Obesity	++	sdLDL Apo B	+ -	Hepatic production
Type 2 diabetes	++	sdLDL Apo B	+ -	Hepatic production and deficient disposal
Type 1 diabetes	+ or ++	+	-	Hepatic production and deficient disposal
NAFLD	++	sdLDL	-	Hepatic production of large VLDL
GSD 1	++	++	-	Hepatic production
Bile duct obstruction		+++		LpX formation from albumin, globulin & lipids.
Cushing's disease	+	+	-	Insulin resistance effects
Lipodystrophy	++		-	Secondary LPL deficiency and diabetes
Stress and trauma	+	+		Increased stress hormones
Pregnancy	+	+		Progesterone effects
CRI	++	+	-	Similar to metabolic syndrome
HIV	+	+		Inflammation, treatments, lipodystrophy
Rheumatoid arthritis	+	+		Inflammation, cytokines

Lupus	+	+		Inflammation, cytokines
Gammopathies	+	+		Antibodies to LDL-R and LPL
<b>b) Hypercholesterolemia (variable HTG)</b>				
Lysosomal acid lipase def.		++	-	Excess cholesterol synthesis (high liver enzymes and excess cholesterol storage),
Bile duct obstruction		+++		LpX formation from albumin, globulin & lipids.
Hypothyroidism	+	++		LDL receptor deficiency
Growth hormone deficiency		+		LDL receptor deficiency
Nephrotic syndrome	+	++		Increased synthesis (low fatty acids)
Saturated and trans fats		+		Dietary excess and LDL-R down-regulation
Anorexia nervosa		+		Nutrient deficiencies

## Endocrine

### OBESITY

In early 2023, the AAP published a clinical pathway guideline aimed at treatment interventions for the 14.4 million children and adolescents who are now obese, noting that it is the most common chronic pediatric disease in the United States (62). It focuses on the child's health status, family system, community context, and the resources for treatment to create the best evidence-based treatment plan. These include 13 Key Action Statements some of which pediatricians and other children healthcare providers are already engaged in including assessing for overweight/obesity, various screening including social determinants of health, and diagnostic studies. As with all children and adolescents, universal lipid screening is recommended but screening should also include screening for pre-diabetes and a hepatic profile to evaluate for the presence of fatty liver disease. Intervention can take place in the medical home or using the chronic care model, engaging in a family-centered non-stigmatizing approach. Referrals for overweight and obese children as young as 2 years-

of-age may be referred for intensive health behavior and lifestyle treatment. Pharmacotherapy can be initiated by the pediatric healthcare provider at age 12 as an adjunct to health behavior and lifestyle treatment. At age 13, adolescents with BMI  $\geq$  120% of the 95<sup>th</sup> percentile for age and sex may be referred to metabolic and bariatric surgery programs.

Obesity has prevailed as the most prominent cardiovascular risk factor beginning in childhood and associated with dietary factors such as excessive consumption of refined carbohydrates, saturated fat and trans fatty acids which not only contribute to weight gain but also cause dyslipidemia (32). Children and adolescents are increasingly referred for obesity associated with dyslipidemia constituting HTG coupled with small dense LDL and low HDL-C (63,64), and with resistance to insulin in muscle and adipose tissue leading to increased plasma insulin and free fatty acids (65). Consumption of high amounts of carbohydrate and fat, being physically unfit, and having close relatives with similar presentations and progression to T2D or manifestations of the metabolic syndrome is often evident (66). Physical characteristics include being overweight or obese; the

---

distribution of fat is generalized but consistently associated with an increased waist circumference, the latter strongly predicting adolescent-onset risk factors (67,68). The skin is hyper-pigmented and thickened at characteristic locations around the neck, knees, elbows, and sites of friction. This condition, called acanthosis nigricans, is associated with insulin resistance (69) and thought by many to be a central component of the metabolic syndrome for which American Indian and Hispanic ethnic groups are particularly predisposed, but Caucasians and African Americans also have high rates (69).

Resistance to insulin action results in mobilization of adipocyte TG and increased fatty acid availability for uptake by muscle and an inverse association with insulin resistance (70). The increased hepatic supply of fatty acids coupled with insulin-stimulated hepatic TG synthesis results in increased VLDL formation and HTG (71) constituting a component of Apo B-containing VLDL particles (72, 73); and increased chylomicron production contributes to the TG level (Figure 2) (74). The effect on lipoproteins is significant since it alters function in favor of atherogenesis. An entropic mechanism involves TG-rich particles exchanging their TG for cholesterol ester via cholesterol-ester transfer protein (CETP) thereby enriching LDL and HDL with TG; a process that is increased by insulin resistance (75). Both LDL and HDL become substrates for hepatic TG lipase, which is up-regulated (76) leading to formation of small dense LDL and small HDL prone to degradation (77, 78).

## TYPE 2 DIABETES

Atherogenic dyslipidemia with increased triglyceride and low HDL-C precedes the onset of prediabetes and T2D in association with persisting insulin resistance (79). LDL glycation and oxidation is increased (80, 81) accounting for increased atherogenesis (82). In the

Treatment Options for T2D in Adolescents and Youth (TODAY) trial, 699 adolescents were studied in three treatment groups receiving metformin alone, metformin with rosiglitazone, and metformin with intensive lifestyle. Twenty one percent (21%) had a high triglyceride or were on a lipid-lowering medication at baseline and 23 % had a high level after three years. During this same period Apo B increased from a mean value of 76.6 mg/dl to 80.1 mg/dl associated with deterioration in glycemic control attributed to a decline in  $\beta$ -cell function. However, the intensive lifestyle arm had significantly lower TG levels after three years (83). The data indicate that T2D in youth is associated with significant cardiovascular risk and difficult to control requiring a multidisciplinary approach (84).

## TYPE 1 DIABETES

Children with type 1 diabetes (T1D) tend to have elevations in TG and cholesterol when insulin is insufficient, reflecting the dependence of lipoprotein lipase on insulin for synthesis and secretion. Increased triglyceride and cholesterol correct after two weeks of intensified insulin delivery (85), and the low HDL-C increases after two months (86). When cases present with severe insulin deficiency and ketoacidosis, TG and cholesterol attain very high levels but normalize on standard treatment with insulin and intravenous fluids (87, 88). These changes reflect the role of insulin in lipoprotein lipase transcription, synthesis, and secretion. Intensified insulin delivery increases Apo A-I and HDL-C even when control of the diabetes reflected by glycosylated hemoglobin remains unchanged (89). However, the relatively normal lipid profiles seen in treated patients with T1D is a paradox since the risk for CVD persists and remains a frequent cause of death (90), but development of renal complications plays a compounding role (91). Subcutaneous insulin bypasses physiological insulin delivery to the liver, and also results in a delayed plasma insulin peak

---

compared to physiological insulin secretion from the pancreas (92), but the resulting delay in chylomicron clearance was not found to be associated with glucose control or elevated fasting TG in adolescents. However, potentially atherogenic apoB-48 containing remnants are increased after a meal challenge (93) and increases in free fatty acids, a correlate of post-prandial TG (94), are harmful to the endothelium by inducing pro-inflammatory effects (95).

Apo C-III, a correlate of triglyceride, has been implicated in the pathogenesis of atherosclerosis (96) in hyperglycemic and insulin resistant states and may have an atherosclerotic role in T1D. The Apo C-III promoter contains both a carbohydrate response element that is responsive to glucose fluctuations (97) and an insulin response element (98) making it susceptible to both glucose fluctuations and insulin deficiency since it is normally down-regulated by insulin. Observations in patients with T1D provide supportive evidence that increased Apo C-III is associated with poor glucose control (99, 100) and being overweight (101). In the DCCT/EDIC T1D cohort with a significant adolescent aged population at onset, Apo C-III was associated with retinopathy (102) and albuminuria (103), implicating Apo C-III and associated TG-rich lipoproteins in microvascular disease (104).

## LIPODYSTROPHY

Congenital and autoimmune lipodystrophies (105) are a group of genetic and acquired disorders characterized by loss of body fat, either partial or generalized (106). The degree of fat loss determines the severity of metabolic complications such as HTG, ectopic fat accumulation, insulin resistance, and progression to diabetes. Loss of adipocytes results in progressive LPL deficiency and chylomicronemia. Reduction in fat intake is effective in reducing risk for pancreatitis; however, insulin resistance and high

carbohydrate intake may result in excess VLDL production requiring the use of prescription omega-3 fatty acids and fibrates. Metformin is the drug of choice for diabetes but trial evidence is lacking for the specific use of glucose-lowering agents in lipodystrophy (106). Loss of adipocytes also leads to acquired leptin deficiency and severe hyperphagia making dietary management of HTG, glucose intolerance, and overt diabetes difficult. Recent approval of recombinant leptin (metreleptin, Amylin Pharmaceuticals) has greatly improved outcomes and quality of life; treatment trials for children are in process. Although formation of leptin antibodies has attenuated the effects (107), follow-up studies suggest that low titers may not result in significant decline in the clinical response.

## HYPOTHYROIDISM

Overt hypothyroidism, either autoimmune or congenital, commonly presents in childhood and at onset may be characterized by an increase in LDL-C and Apo B because of a reduced number of LDL receptors (85). In subclinical hypothyroidism the lipid profile is characterized by normal or slightly elevated total cholesterol levels and LDL-C in adults (108) but this observation has been less evident in children (109).

## GROWTH HORMONE

Growth hormone deficiency and excess are both causes of hyperlipidemia. GH deficiency down-regulates the LDL receptor (110) and can result in elevations in total cholesterol and LDL-C that are reduced by treatment (111); whereas excess GH tends to mobilize fatty acids and increase VLDL triglyceride (112, 113), as seen in cases with acromegaly or gigantism in childhood.

## Hepatic



---

## NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

NAFLD, manifesting as ectopic fat deposition in the liver, is observed in obese children and adolescents in association with increased visceral fat and features of metabolic syndrome (114). The condition is associated with insulin resistance and high TG independent of intra-myocellular fat.

## HEPATITIS C

Hepatitis C is associated with steatosis and a unique dysmetabolic syndrome characterized by insulin resistance, inflammation-induced atherosclerosis but a low cholesterol level.(115) The virus interferes with distal steps in cholesterol synthesis and with Apo B secretion. Risk for atherosclerosis is attributed to vascular inflammation (116, 117).

## GLYCOGEN STORAGE DISEASE (GSD)

GSDs are associated with HTG (118, 119) and present as significant diagnostic and therapeutic challenges since the onset is at an early age. Type I GSD is caused by a recessively inherited defect in glucose-6-phosphatase, and accounts for more than 60% of the GSD types involving the liver and results in the highest TG levels due to excessive VLDL production. It presents during the first year of life with severe hypoglycemia and hepatomegaly caused by the accumulation of hepatic glycogen. Increased VLDL production is associated with TG-rich particles containing excess Apo C-III and Apo E (120). In addition, the metabolic consequences of impeded glucose formation and excessive anaerobic glycolysis manifest as hypoglycemia with lactic acidemia, hyperuricemia and dyslipidemia. Impaired growth factor production and acidosis result in poor growth and delayed puberty. Many of these effects, including

impaired growth, can be reversed by sustained correction of hypoglycemia with dietary sources of complex carbohydrate. Restoration of euglycemia results in less stress-hormone induced stimulation of metabolic excesses derived from activated anaerobic glycolysis. Continuous complex carbohydrate feeding regimens are prescribed as frequent meals and supplementation with corn-starch. However, to effectively normalize the TG, frequent corn-starch dosing is needed to achieve blood glucose levels continuously above 75 mg/dL, especially at night. This approach involves high carbohydrate intakes, which in the long term may increase VLDL production often resulting in requirement for lipid lowering medications.

## Renal

Nephrosis is associated with increased cholesterol synthesis and increased TG attributed to lipoprotein lipase inhibition (121). A two-phase dyslipidemia occurs in which TG hydrolysis by lipoprotein lipase is impaired when albumin levels are too low to remove fatty acids at an adequate rate after hydrolysis (122). Association with atherosclerosis is in part attributed to increases in Lp(a) and Apo C-III (123,124). Findings in chronic kidney disease in children resemble those in adults and simulate atherogenic dyslipidemia seen in the metabolic syndrome.

## Immune

Immune causes are rare in adults and children but should be considered in specific clinical situations. HIV (human immunodeficiency virus) is associated with partial lipodystrophy and insulin resistance. The lipid profile before treatment shows a high triglyceride, low HDL-C, and small dense LDL (125), and subsequent treatment with protease inhibitors can make the situation worse (126). In gammopathies such as in Hodgkin's disease, antibodies can sequester factors required for LPL activity (127) or they can impede

lipoprotein uptake by receptors (128). Although less frequent than in adults, monoclonal or oligoclonal gammopathies, predominantly IgG mediated, occur in children with various autoimmune diseases, hematologic diseases, malignancies, transplantations, and immunodeficiencies (129).

## PHARMACOLOGICAL CAUSES

Pharmacological agents have significant effects on plasma lipids. In some cases the mechanism is known but is frequently uncertain or unknown. The potential

for causing dyslipidemia is particularly important in a patient that has an underlying genetic predisposition. Changing the offending medication or treating the dyslipidemia are both options, especially when the disease requires long term management and alternative medications are limited or not available. Each medication class has characteristic effects on the lipid profile but some, such as glucocorticoids, oral estrogens, and alcohol, may increase HDL-C and others may increase both cholesterol and triglyceride (Table 4).

**Table 4. Classes of Medications and Examples Causing Hypertriglyceridemia in Childhood**

Medication Class	TG	TC	HDL-C	Examples
Glucocorticoids	++	+	+	prednisone, hydrocortisone
Oral estrogens	+	+	+	ethinyl estradiol
Anabolic steroids	+	+	-	depo-testosterone, oxandrolone
Estrogen receptor blockade	+			tamoxifen
Retinoids	+		-	isotretinoin
Immune suppressants	+	+		cyclosporine, sirolimus, tacrolimus
Protease inhibitors	+		-	ritonavir, nelfinavir and indinavir
Diuretics	++		-	chlorthiazide, diuril
Antipsychotics	+		-	clozapine, olanzapine, cimetidine
Beta blockers	+		-	propranolol, labetalol
Bile acid sequestrants	+			cholestyramine, colestipol, cholestevlam
Alcohol	+		+	spirits, wines, beers

### Glucocorticoids

Glucocorticoids, especially in high doses, cause significant combined dyslipidemia and the effects on lipids may be compounded by other medications, the disease itself, or the patient's genetic background. Lipid changes during treatment of chronic illnesses show elevations in triglyceride and LDL-C due to increased production, with variable changes in HDL-C but often increases (130). The effects may depend on the preparation used, dose and disease being treated (131). Combination drug therapy with L-asparaginase,

an inhibitor of lipoprotein lipase, used for the induction phase in leukemia therapy can cause marked elevations in TG and is also diabetogenic (132). Lipid-lowering to prevent acute pancreatitis and thrombotic events is possible without stopping the chemotherapy.

### Estrogens

Oral estrogens such as ethinyl estradiol usually prescribed with progestogen as oral contraceptives increase the production rate of Apo B-containing lipoproteins but the increase is counterbalanced by an

---

increased catabolic rate (133). This finding accounts for only a slight increase in cholesterol and triglyceride within the normal range in adolescent girls (134), however interaction with obesity is possible with respect to LDL-C and fasting glucose (135). Reducing the dose of estrogen from the previously prescribed high dose preparations was effective in offsetting cardiovascular risk, however interactions with other risk factors such as smoking may occur (136).

Estrogen receptor blockade with tamoxifen has been associated with mild hyper-TG in women treated for breast cancer or its prevention, but it has rare use in childhood except for treatment of pubertal gynecomastia.

### **Retinoids**

Retinoids such as isotretinoin (Accutane, 13-cis-retinoic acid) is indicated for treatment of severe nodular acne and can be prescribed for as long as 20 weeks, but careful monitoring is required. Severe HTG resulting from lipoprotein lipase inhibition frequently occurs, and can cause acute pancreatitis (137, 138). It acts via retinoic acid and retinoid x receptors (116) and there is also ongoing interest in use for cancer therapy and chemoprevention (139, 140).

### **Immune Suppressants**

Cyclosporine (141), sirolimus (142), and tacrolimus are used in transplant patients and immune-mediated diseases in children requiring long term treatment and monitoring when indicated (143, 144). The mechanism is via down-regulation of hepatic 7 $\alpha$ -hydroxylase and myocyte and adipocyte lipoprotein lipase down-regulation (145).

### **Protease Inhibitors**

Protease inhibitors are associated with HTG and low HDL-C and add to the effects of the lipodystrophy syndrome occurring before anti-retroviral treatment of human immunodeficiency virus infections in pediatric cases, particularly during adolescence (146). Drugs such as ritonavir, nelfinavir and indinavir cause more severe dyslipidemia than others (147).

Nucleoside reverse transcriptase inhibitors can also cause TG and cholesterol elevations (148).

### **Bile Acid Sequestrants**

Bile acid sequestrants should be avoided in cases with mixed dyslipidemia since they elevate TG (149). Fibrates or omega-3s, although effective in lowering TG, may transiently raise LDL-C during lipolysis of VLDL and conversion to LDL.

### **Diuretics**

Diuretics including thiazides and loop diuretics such as furosemide alone or as combination therapy for hypertension raise cholesterol and TG and lower HDL-C in a dose dependent manner and more so in African Americans (150).

### **Beta-Blockers**

Beta-blockers increase TG and lower HDL-C especially preparations without alpha-blocking activity but have rare indication in childhood since combination therapy for hypertension does not have trial evidence, (151) but they are used for management of arrhythmias.

### **Antipsychotics**

Antipsychotics have pediatric psychiatric indications and agents such as clozapine and olanzapine induce HTG. However, it is not clear if the effect is independent of HTG induced by increased appetite

---

and resulting weight gain typical of this class of medications and may require prescription changes or behavioral modification when possible (152).

### **Anabolic Steroids**

Covert use of anabolic steroids in adolescent athletes and should be suspected with HTG and unusually low HDL-C levels. Medical use of oxandrolone for growth or androgens for aplastic anemia is rare and seldom has an indication.

### **Alcohol**

Alcohol consumption has dyslipidemic effects, particularly with chronic use (153), and promotes development of fatty liver disease and associated HTG (154), particularly in susceptible Hispanic adolescents or in those with underlying genetic predisposition. As with steroids and estrogens, a typical presentation is with a markedly increased TG level with a higher-than-expected HDL-C (Table 4).

## **MANAGEMENT**

### **General**

Obesity and insulin resistance associated with dietary excess and inactivity should be assessed as potential targets in the therapeutic plan. If the identifiable cause(s) of secondary HTG cannot be corrected or optimally managed, as in patients with severe disorders or on essential drug therapy for their underlying diseases, lifestyle management is a priority. A six month trial of weight management by restricting excessive calories, saturated fat, and refined carbohydrate in the diet is recommended by the NHLBI Expert Panel (14). There is also consensus

that diet, exercise and behavioral modalities should be used in combination for successful outcomes in children (155), which are dependent on self-motivation, family support, and access to skilled instruction, preferably provided by a dietitian with pediatric experience. A comprehensive team approach for use of exercise and behavioral modalities is considered optimal. Successful programs serve as role models for providers, particularly from centers with resources for team approaches similar to those designed for obesity management (156).

### **Drug Therapy**

Treatment of the primary disorder is the first priority, i.e., treating HTG associated with T2D diabetes requires specific therapies based on the severity of the TG elevation and response to lifestyle. Rare disorders require specific therapies such as complex carbohydrates for maintaining euglycemia in GSD, and leptin therapy for lipodystrophy (discussed above). If pharmaceutical agents are the cause, modification of the treatment plan can be considered in consultation with the primary specialist. Sunil et al recently summarized medications targeted for HTG (157) as well as hypercholesterolemia and the former are summarized in figure 4 and several are discussed in detail herein. Unfortunately, none of these medications are approved below age 18 years-of-age, therefore treatment of HTG in children and adolescents is largely restricted to lifestyle changes. The most important aspect of dietary counseling is also discerning if the HTG is associated with insulin resistance where lowering simple sugars and carbohydrates is key or hyperchylomicronemia where fat restriction is paramount or where these disorders overlap.

Therapeutic target/agent	Medications	TG-lowering mechanism
Fibric acid derivatives	Gemfibrozil	Decrease VLDL-C production and increase LPL activity
	Fenofibrate	
Omega 3 Fatty acid	EPA/DHA	Inhibit DGA, reduce VLDL-C synthesis, and increase rate of peroxisomal beta oxidation in the liver
	Icosapent ethyl	
ApoC3	Volanesorsen (ASO)	Targets mRNA to reduce apoC3 production Eventually promotes hydrolysis of TG by LPL
	Anti apoC3 ASO conjugated to GalNac	
MTP	Lomitapide	Reduces intestinal chylomicron and hepatic VLDL and LDL production
ANGPTL3	Evinacumab (ANGPTL3 mAb)	Blocks lipases, promotes VLDL remodeling ASO reducing ANGPTL3 synthesis
	Vupanorsen (ASO targeting ANGPTL3 mRNA in the liver)	

ANGPTL3, angiopoietin-like 3 protein; ApoC3, apolipoprotein C3; ASO, antisense oligonucleotide; DGA, diacylglycerol acyltransferase; DHA, docosahexanoic acid; EPA, eicosapentanoic acid; GalNac, triantennary *N*-acetyl galactosamine; LDL, low-density lipoprotein cholesterol; LPL, lipoprotein lipase; mAb, monoclonal antibody; mRNA, messenger RNA; MTP, microsomal triglyceride transfer protein; TG, triglyceride; VLDL, very-low-density lipoprotein.  
None of these medications shown are FDA approved for children <18 years-of-age.

**Figure 4. Triglyceride lowering medications. From Ref. 157.**

## STATINS

Statins which are not described in figure 4 lower cholesterol, specifically LDL-C and have minimal effect on HTG. However, for commonly encountered dyslipidemia there is good reason to follow established guidelines to reduce the future CVD risk through the use of statin therapy (14). If a six-month trial of intensive lifestyle is not effective in reaching the recommended goal, the LDL-C and non-HDL-C become targets using appropriate agents such as statins. As discussed previously, non-HDL-C is a preferred target for individuals with mild to moderate TG elevations (150-499 mg/dl) as recommended by

the 2011 expert NHLBI panel (14). For LDL-C and non-HDL-C above 95<sup>th</sup> percentiles in the presence of HTG and at least one other risk factor, statin therapy is indicated selecting from approved statins for children over age 10 years (15). The reported statin association with type 2 diabetes (158,159) should be considered when obesity and associated genetic risk for diabetes is present.

It should be emphasized that when statin treatment is indicated for drug-induced hypercholesterolemia, care should be taken to avoid interactions with drugs that are metabolized by pathways utilizing cytochrome P450 enzymes, such as CYP3A4 for atorvastatin,



---

lovastatin and simvastatin and CYP2C9 for fluvastatin and rosuvastatin (159). Drugs such as clarithromycin, cyclosporine A, diltiazem, erythromycin, ketoconazole, itraconazole, mibefradil, midazolam, nefazodone, nifedipine, protease inhibitors, quinidine, sildenafil, terbinafine, verapamil and warfarin are CYP3A4 utilizers and will raise the statin levels when used together, thus increasing risk of toxicity. Likewise, alprenolol, diclofenac, fluconazole, hexobarbital, n-desmethyldiazepam, tolbutamide and warfarin are CYP2C9 utilizers and will be incompatible with fluvastatin and rosuvastatin. Several of these drugs have common pediatric usage including certain antibiotics and antifungal agents.

## FIBRATES

Based on adult evidence of harmful effects of TG-rich lipoproteins, small dense LDL, and remnant lipoproteins derived from VLDL and chylomicrons (160) and the metabolic effects of TG and associated increase in fatty acids (161), pharmacological TG lowering in childhood is indicated for selected cases resistant to lifestyle (14). Individuals with severe isolated HTG at risk for acute pancreatitis should have a trial of a TG-lowering agent such as a fibrate (i.e., gemfibrozil or fenofibrate), beginning with the lowest available dose while monitoring for adverse effects. Fibrates, approved for use over age 18 years, have limited trial evidence in children but a fibrate (bezafibrate, not available in the United States) was shown to be safe when used for children with familial hypercholesterolemia before statins were available for use (162). It is however notable that few adult trials have shown benefit of fibrates on cardiovascular event reduction. Niacin while historically used (163), no longer has a place in the management of dyslipidemia.

## OMEGA-3 FATTY ACIDS

Omega-3-fatty acids have appeal as a potential TG-lowering agent for children because of their relatively low adverse effect profile and recent availability as a prescription grade preparation following purification to remove heavy metals and fatty acids (164). Although adults have had up to 30% TG lowering with 4-gram doses, 2 gram doses are less effective and increased LDL-C is a recognized adverse effect (165,166). but the LDL-C to HDL-C ratio is unchanged (167). A retrospective survey of children treated for TG lowering with omega-3 fatty acids at a dose of 0.5 to 1 gram per day, did not show significant TG lowering suggesting that prescription of relatively low doses may not be helpful. The study supports use of higher doses in combination with lifestyle measures. A high purity prescription form of icosapent ethyl (eicosapentaenoic acid ethyl ester), lowers TG while lowering LDL particle concentration and LDL-C in cases with TG over 500mg/L (168, 169), but it is not yet available for use under 18 years of age, however it appears to be a reasonable consideration for testing in pediatric settings. The free fatty acid form as shown in the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial is effective for TG-lowering (170), but not yet available for use in children. Non-prescription marine omega-3s can be safely used if patients are instructed on what to look for on the label (e.g., distilled, USP approved) and specific marine sources with high concentrations are recommended (171).

## SEVERE SECONDARY HTG

Treatment for HTG with levels above 1000 mg/dl in patients with partial defects in chylomicron clearance by LPL or its co-factors requires total dietary fat

restriction for 72 hours followed by dietary management in the longer term. The approach is similar to the management of homozygous familial chylomicronemia for which there is more information (172) (reviewed in another chapter). It should be recognized that small increments in fat can cause striking increases in plasma TG because when TG levels saturate LPL activity, any additional TG entering the plasma will face zero order kinetics and increase the TG in a non-linear fashion. TG can be substantially lowered by restricting dietary fat to less than 15% of the total daily caloric intake and cases vary in their response to fibrates depending on their effect on residual lipoprotein lipase and on suppression of hepatic TG production. Adherence to a very low-fat diet requires supplementation with linoleic acid and fat-soluble vitamins (A, D, E and K), but frequent monitoring is advised. Supplemental medium chain triglycerides (MCT) may be beneficial in providing additional calories and improving compliance. Fenofibrate can be helpful in cases with residual lipoprotein lipase activity and also may reduce hepatic TG production. New agents are being developed to increase clearance and/or reduce the production of triglyceride-rich lipoproteins, but their clinical efficacy, cost effectiveness, and indications, especially in

children, are yet to be established (173).

## CONCLUSION

In addition to obesity accompanied by metabolic syndrome, other common and rare causes of secondary dyslipidemia require diagnosis-specific management strategies. Identification and prioritization of reversible causes and risk factors, use of comprehensive lifestyle approaches, and optimal choice of medications based on guidelines can lead to improved outcomes. Lifestyle modification with selective prescription of medications designed to reduce risk of cardiovascular disease is indicated for individuals with intermediate TG levels ranging from 150-499 mg/dL, but severely elevated levels imposing risk for acute pancreatitis, require more intense dietary restriction combined with TG-lowering medications. The results of AAP's recent recommendation of a more aggressive approach to treatment of childhood obesity await outcome data. Since non-HDL-C is a known predictor of cardiovascular disease and represents an estimate of all atherogenic lipoprotein particles TG-rich lipoproteins, it is recommended as a preferred target especially in most cases with intermediate elevations of TG.

## REFERENCES

1. Blackett PR, Wilson DP, McNeal CJ. Secondary hypertriglyceridemia in children and adolescents. *Journal of clinical lipidology*. 2015 Sep 1;9(5):S29-40.
2. Jung MK, Yoo EG. Hypertriglyceridemia in obese children and adolescents. *Journal of obesity & metabolic syndrome*. 2018 Sep;27(3):143.
3. Shah AS, Wilson DP. Primary hypertriglyceridemia in children and adolescents. *Journal of Clinical Lipidology*. 2015 Sep 1;9(5):S20-8.
4. Shah AS, Wilson DP. Genetic disorders causing hypertriglyceridemia in children and adolescents. *Endotext* [Internet]. 2020 Jan 22.
5. Sunil B, Ashraf AP. Childhood Hypertriglyceridemia: Is It Time for a New Approach?. *Current Atherosclerosis Reports*. 2022 Apr;24(4):265-75.
6. Magge SN, Goodman E, Armstrong SC, Daniels S, Corkins M, de Ferranti S, Golden NH, Kim JH, Schwarzenberg SJ, Sills IN, Casella SJ. The metabolic syndrome in children and adolescents: shifting the focus to cardiometabolic risk factor clustering. *Pediatrics*. 2017 Aug 1;140(2).
7. Reisinger C, Nkeh-Chungag BN, Fredriksen PM, Goswami N. The prevalence of pediatric metabolic syndrome—A critical look on the discrepancies between definitions and its clinical importance. *International Journal of Obesity*. 2021 Jan;45(1):12-24.
8. Christian Flemming GM, Bussler S, Körner A, Kiess W. Definition and early diagnosis of metabolic syndrome in children. *Journal of Pediatric Endocrinology and Metabolism*. 2020 Jul

28;33(7):821-33.

9. Weihe P, Weihrauch-Blüher S. Metabolic syndrome in children and adolescents: diagnostic criteria, therapeutic options and perspectives. *Current obesity reports*. 2019 Dec;8:472-9.

10. Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH 2008 Prevalence of the metabolic syndrome among U.S. adolescents using the definition from the International Diabetes Federation. *Diabetes care* 31:587-589

11. Regis A. The CHILd 1 diet: from strategy to practicality. *Pediatric Annals*. 2013 Sep 1;42(9):e188-90.

12. Selvarj K, Olave-Pichon A, Benuck I, et al. Characteristics of children referred to a lipid clinic before and after the universal screening guidelines. *Clinical Pediatrics*. (2019) 58(6):656-664.

13. Capra ME, Biasucci G, Banderali G, Pederiva C. Nutritional Treatment of Hypertriglyceridemia in Childhood: From Healthy-Heart Counselling to Life-Saving Diet. *Nutrients*. 2023 Feb 22;15(5):1088.

14. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: summary report. *Pediatrics*. (2011) 128:S213-56; Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: full report. U.S. Department of Health and Human Services. (2011)]

15. White JS. Sucrose, HFCS, and Fructose: History, Composition, Applications, and Production. Chapter 2 in J.M. Rippe (ed.), *Fructose, High Fructose Corn Syrup, Sucrose and Health, Nutrition and Health*. Springer Science+Business Media New York. (2014) ISBN 978-1-4899-8077-9

16. High Fructose Corn Syrup Questions and Answers. U.S. Food and Drug Administration. (2018)

17. White JS. Misconceptions about high-fructose corn syrup: Is it uniquely responsible for obesity, reactive dicarbonyl compounds, and advanced glycation endproducts? *Journal of Nutrition*. (2009) 139(6):1219S-1227S

18. Lee JH, Duster M, Roberts T, Devinsky O. United States Dietary Trends Since 1800: Lack of Association Between Saturated Fatty Acid Consumption and Non-communicable Diseases. *Front Nutr*. 2022 Jan 13;8:748847. doi: 10.3389/fnut.2021.748847. PMID: 35118102; PMCID: PMC8805510.

19. Drozdowski LA, Thomson AB. Intestinal sugar transport. *World J Gastroenterol*. (2006) 12(11):1657-70.

20. Chernecky CC, Berger BJ. Glucose tolerance test (GTT, OGTT) – blood. In: Chernecky CC, Berger BJ, eds. *Laboratory Tests and Diagnostic Procedures*. 6th ed. Philadelphia, PA: Elsevier Saunders. (2013) 591-593

21. Kwiterovich PO 2010 Lipid, apolipoprotein, and lipoprotein metabolism: implications for the diagnosis and treatment of dyslipidemia: Wolters Kluwer/Lippincott Williams & Wilkins

22. Smelt AH, de Beer F 2004 Apolipoprotein E and familial

dysbetalipoproteinemia: clinical, biochemical, and genetic aspects. *Seminars in vascular medicine* 4:249-257

23. Berenson GS, Srinivasan SR, Bao W, Newman WP, 3rd, Tracy RE, Wattigney WA 1998 Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. *The New England journal of medicine* 338:1650-1656

24. McGill HC, Jr., McMahan CA, Zieske AW, Sloop GD, Walcott JV, Troxclair DA, Malcom GT, Tracy RE, Oalmann MC, Strong JP 2000 Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. *Arteriosclerosis, thrombosis, and vascular biology* 20:1998-2004

25. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*. 2011 May 24;123(20):2292-333.

26. Hussain A, Ballantyne CM, Saeed A, Virani SS. Triglycerides and ASCVD risk reduction: recent insights and future directions. *Current Atherosclerosis Reports*. 2020 Jul;22:1-0.

27. Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. *The American journal of cardiology*. 2016 Jul 1;118(1):138-45.

28. Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. *Circulation research*. 2016 Feb 19;118(4):547-63.

29. McGill HC, Jr., McMahan CA, Herderick EE, Tracy RE, Malcom GT, Zieske AW, Strong JP 2000 Effects of coronary heart disease risk factors on atherosclerosis of selected regions of the aorta and right coronary artery. PDAY Research Group. *Pathobiological Determinants of Atherosclerosis in Youth*. *Arteriosclerosis, thrombosis, and vascular biology* 20:836-845

30. Frontini MG, Srinivasan SR, Xu J, Tang R, Bond MG, Berenson GS 2008 Usefulness of childhood non-high density lipoprotein cholesterol levels versus other lipoprotein measures in predicting adult subclinical atherosclerosis: the Bogalusa Heart Study. *Pediatrics* 121:924-929

31. Centers for Disease Control and Prevention (CDC) Prevalence of abnormal lipid levels among youths: United States, 1999–2006. *MMWR Morb Mortal Wkly Rep*. 2010;59:29–33

32. Skinner AC, Ravanbakht SN, Skelton JA, Perrin EM, Armstrong SC. Prevalence of Obesity and Severe Obesity in US Children, 1999–2016. *Pediatrics*. 2018 Mar;141(3):e20173459. doi: 10.1542/peds.2017-3459. Erratum in: *Pediatrics*. 2018 Sep;142(3): PMID: 29483202; PMCID: PMC6109602.

33. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K, American Heart A 2003 American Heart Association

guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. *Circulation* 107:1562-1566

34. Wilson DP, McNeal C, Blackett P 2015 Pediatric dyslipidemia: recommendations for clinical management. *Southern medical journal* 108:7-14

35. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem.* (1972) 18:499-502.]

36. Martin SS, Blaha MJ, Elshazly MB, Toth PP, Kwiterovich PO, Blumenthal RS, Jones SR. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. *Jama.* 2013 Nov 20;310(19):2061-8.

37. Sajja A, Park J, Sathiyakumar V, Varghese B, Pallazola VA, Marvel FA, et al. Comparison of Methods to Estimate LowDensity Lipoprotein Cholesterol in Patients With High Triglyceride Levels. *JAMA Netw Open.* 2021;4(10):e2128817

38. Sampson M, Ling C, Sun Q, Harb R, Ashmaig M, Warnick R, Sethi A, Fleming JK, Otvos JD, Meeusen JW, Delaney SR. A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and/or hypertriglyceridemia. *JAMA cardiology.* 2020 May 1;5(5):540-8.

39. Steyn N, Rossouw HM, Pillay TS, Martins J. Comparability of calculated LDL-C with directly measured LDL-C in selected paediatric and adult cohorts. *Clinica Chimica Acta.* 2022 Dec 1;537:158-66.

40. Chan KK, Dickerson JA. Assessment of LDL-C Calculation Using the Newly Adopted NIH LDL-C Equation in a Pediatric Population. *Clinical Chemistry.* 2022 Oct 6;68(10):1338-9.

41. Garoufi A, Drakatos A, Tsentidis C, Klinaki E, Paraskakis I, Marmarinos A, Gourgiotis D. Comparing calculated LDL-C with directly measured LDL-C in healthy and in dyslipidemic children. *Clinical biochemistry.* 2017 Jan 1;50(1-2):16-22.

42. Johansen CT, Hegele RA 2011 Genetic bases of hypertriglyceridemic phenotypes. *Current opinion in lipidology* 22:247-253

43. Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, Boren J, Bruckert E, Catapano AL, Descamps OS, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AF, Stroes E, Taskinen MR, Tybjaerg-Hansen A, Watts GF, Wiklund O, European Atherosclerosis Society Consensus P 2014 The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. *The lancet. Diabetes & endocrinology* 2:655-666

44. Brunzell JD, Schrott HG 2012 The interaction of familial and secondary causes of hypertriglyceridemia: role in pancreatitis. *Journal of clinical lipidology* 6:409-412

45. Julien P, Vohl MC, Gaudet D, Gagne C, Levesque G,

Despres JP, Cadelis F, Brun LD, Nadeau A, Ven Murthy MR 1997 Hyperinsulinemia and abdominal obesity affect the expression of hypertriglyceridemia in heterozygous familial lipoprotein lipase deficiency. *Diabetes* 46:2063-2068

46. Gupta M, Liti B, Barrett C, Thompson PD, Fernandez AB. Prevention and management of hypertriglyceridemia-induced acute pancreatitis during pregnancy: a systematic review. *The American Journal of Medicine.* 2022 Jun 1;135(6):709-14.

47. Kelishadi R, Poursafa P. A review on the genetic, environmental, and lifestyle aspects of the early-life origins of cardiovascular disease. *Current problems in pediatric and adolescent health care.* 2014 Mar 1;44(3):54-72.

48. Zhang Z, Gillespie C, Welsh JA, Hu FB, Yang Q. Usual intake of added sugars and lipid profiles among the US adolescents: National Health and Nutrition Examination Survey, 2005–2010. *Journal of Adolescent Health.* 2015 Mar 1;56(3):352-9.

49. Bello-Chavolla OY, Kuri-García A, Ríos-Ríos M, Vargas-Vázquez A, Cortés-Arroyo JE, Tapia-González G, Cruz-Bautista I, Aguilar-Salinas CA. Familial combined hyperlipidemia: current knowledge, perspectives, and controversies. *Revista de investigacion clinica.* 2018 Nov 15;70(5):224-36.

50. Tg, HDL Working Group of the Exome Sequencing Project NHL, Blood I, Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitzel NO, Lange LA, Lu Y, Tang ZZ, Zhang H, Hindy G, Masca N, Stirrups K, Kanoni S, Do R, Jun G, Hu Y, Kang HM, Xue C, Goel A, Farrall M, Duga S, Merlini PA, Asselta R, Girelli D, Olivieri O, Martinelli N, Yin W, Reilly D, Speliotes E, Fox CS, Hveem K, Holmen OL, Nikpay M, Farlow DN, Assimes TL, Franceschini N, Robinson J, North KE, Martin LW, DePristo M, Gupta N, Escher SA, Jansson JH, Van Zuydam N, Palmer CN, Wareham N, Koch W, Meitinger T, Peters A, Lieb W, Erbel R, König IR, Kruppa J, Degenhardt F, Gottesman O, Bottinger EP, O'Donnell CJ, Psaty BM, Ballantyne CM, Abecasis G, Ordovas JM, Melander O, Watkins H, Orho-Melander M, Ardisson D, Loos RJ, McPherson R, Willer CJ, Erdmann J, Hall AS, Samani NJ, Deloukas P, Schunkert H, Wilson JG, Kooperberg C, Rich SS, Tracy RP, Lin DY, Altshuler D, Gabriel S, Nickerson DA, Jarvik GP, Cupples LA, Reiner AP, Boerwinkle E, Kathiresan S 2014 Loss-of-function mutations in APOC3, triglycerides, and coronary disease. *The New England journal of medicine* 371:22-31

51. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A 2014 Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. *The New England journal of medicine* 371:32-41

52. Barker DJ, Thornburg KL 2013 Placental programming of chronic diseases, cancer and lifespan: a review. *Placenta* 34:841-845

53. Reinehr T, Kleber M, Toschke AM 2009 Small for gestational age status is associated with metabolic syndrome in

overweight children. *European journal of endocrinology / European Federation of Endocrine Societies* 160:579-584

54. Lindquist S, Hernell O 2010 Lipid digestion and absorption in early life: an update. *Current opinion in clinical nutrition and metabolic care* 13:314-320

55. Adamkin DH, Radmacher PG 2014 Current trends and future challenges in neonatal parenteral nutrition. *Journal of neonatal-perinatal medicine*

56. Johnson PJ 2014 Review of macronutrients in parenteral nutrition for neonatal intensive care population. *Neonatal network : NN* 33:29-34

57. Brufani C, Fintini D, Giordano U, Tozzi AE, Barbetti F, Cappa M 2011 Metabolic syndrome in italian obese children and adolescents: stronger association with central fat depot than with insulin sensitivity and birth weight. *International journal of hypertension* 2011:257168

58. Lee S, Bacha F, Gungor N, Arslanian SA 2006 Racial differences in adiponectin in youth: relationship to visceral fat and insulin sensitivity. *Diabetes care* 29:51-56

59. Reinehr T, Kulle A, Wolters B, Knop C, Lass N, Welzel M, Holterhus PM 2014 Relationships between 24-hour urinary free cortisol concentrations and metabolic syndrome in obese children. *The Journal of clinical endocrinology and metabolism* 99:2391-2399

60. Schnackenberg CG, Costell MH, Krosky DJ, Cui J, Wu CW, Hong VS, Harpel MR, Willette RN, Yue TL 2013 Chronic inhibition of 11 beta -hydroxysteroid dehydrogenase type 1 activity decreases hypertension, insulin resistance, and hypertriglyceridemia in metabolic syndrome. *BioMed research international* 2013:427640

61. Goran MI, Gower BA 2001 Longitudinal study on pubertal insulin resistance. *Diabetes* 50:2444-2450

62. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. *Pediatrics* (2023) 151 (2): e2022060640. <https://doi.org/10.1542/peds.2022-060640>

63. Copeland KC, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K, Kaufman FR, Linder B, Marcovina S, McGuigan P, Pyle L, Tamborlane W, Willi S, Group TS 2011 Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. *The Journal of clinical endocrinology and metabolism* 96:159-167

64. Giannini C, Santoro N, Caprio S, Kim G, Lartaud D, Shaw M, Pierpont B, Weiss R 2011 The triglyceride-to-HDL cholesterol ratio: association with insulin resistance in obese youths of different ethnic backgrounds. *Diabetes care* 34:1869-1874

65. Olefsky JM, Farquhar JW, Reaven GM 1974 Reappraisal of the role of insulin in hypertriglyceridemia. *The American journal of medicine* 57:551-560

66. Vassy JL, Shrader P, Yang Q, Liu T, Yesupriya A, Chang

MH, Dowling NF, Ned RM, Dupuis J, Florez JC, Khoury MJ, Meigs JB 2011 Genetic associations with metabolic syndrome and its quantitative traits by race/ethnicity in the United States. *Metabolic syndrome and related disorders* 9:475-482

67. Burns SF, Arslanian SA 2009 Waist circumference, atherogenic lipoproteins, and vascular smooth muscle biomarkers in children. *The Journal of clinical endocrinology and metabolism* 94:4914-4922

68. Lee S, Bacha F, Arslanian SA 2006 Waist circumference, blood pressure, and lipid components of the metabolic syndrome. *The Journal of pediatrics* 149:809-816

69. Stoddart ML, Blevins KS, Lee ET, Wang W, Blackett PR, Cherokee Diabetes S 2002 Association of acanthosis nigricans with hyperinsulinemia compared with other selected risk factors for type 2 diabetes in Cherokee Indians: the Cherokee Diabetes Study. *Diabetes care* 25:1009-1014

70. Pan DA, Lillioja S, Kriketos AD, Milner MR, Baur LA, Bogardus C, Jenkins AB, Storlien LH 1997 Skeletal muscle triglyceride levels are inversely related to insulin action. *Diabetes* 46:983-988

71. Tobey TA, Greenfield M, Kraemer F, Reaven GM 1981 Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics, and plasma triglyceride levels in normotriglyceridemic man. *Metabolism: clinical and experimental* 30:165-171

72. Basu A, Basu R, Shah P, Vella A, Rizza RA, Jensen MD 2001 Systemic and regional free fatty acid metabolism in type 2 diabetes. *American journal of physiology. Endocrinology and metabolism* 280:E1000-1006

73. Zhang YL, Hernandez-Ono A, Ko C, Yasunaga K, Huang LS, Ginsberg HN 2004 Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids. I. Differential response to the delivery of fatty acids via albumin or remnant-like emulsion particles. *The Journal of biological chemistry* 279:19362-19374

74. Nogueira JP, Maraninchi M, Beliard S, Padilla N, Duvillard L, Mancini J, Nicolay A, Xiao C, Vialettes B, Lewis GF, Valero R 2012 Absence of acute inhibitory effect of insulin on chylomicron production in type 2 diabetes. *Arteriosclerosis, thrombosis, and vascular biology* 32:1039-1044

75. Coniglio RI, Merono T, Montiel H, Malaspina MM, Salgueiro AM, Otero JC, Ferraris R, Schreier L, Brites F, Gomez Rosso L 2012 HOMA-IR and non-HDL-C as predictors of high cholesteryl ester transfer protein activity in patients at risk for type 2 diabetes. *Clinical biochemistry* 45:566-570

76. Deeb SS, Zambon A, Carr MC, Ayyobi AF, Brunzell JD 2003 Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. *Journal of lipid research* 44:1279-1286

77. Chapman MJ, Ginsberg HN, Amarencio P, Andreotti F,



- Boren J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A, Watts GF, European Atherosclerosis Society Consensus P 2011 Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. *European heart journal* 32:1345-1361
78. Ginsberg HN 2002 New perspectives on atherogenesis: role of abnormal triglyceride-rich lipoprotein metabolism. *Circulation* 106:2137-2142
79. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK 1990 Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? *Jama* 263:2893-2898
80. Cohen MP, Lautenslager G, Shea E 1993 Glycated LDL concentrations in non-diabetic and diabetic subjects measured with monoclonal antibodies reactive with glycated apolipoprotein B epitopes. *European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies* 31:707-713
81. Bowie A, Owens D, Collins P, Johnson A, Tomkin GH 1993 Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? *Atherosclerosis* 102:63-67
82. Wang W, Khan S, Blackett P, Alaupovic P, Lee E 2013 Apolipoproteins A-I, B, and C-III in young adult Cherokee with metabolic syndrome with or without type 2 diabetes. *Journal of clinical lipidology* 7:38-42
83. TODAY Study Group 2013 Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. *Diabetes care* 36:1758-1764
84. George MM, Copeland KC 2013 Current treatment options for type 2 diabetes mellitus in youth: today's realities and lessons from the TODAY study. *Current diabetes reports* 13:72-80
85. Sherwin RS, Tamborlane WV, Genel M, Felig P 1980 Treatment of juvenile-onset diabetes by subcutaneous infusion of insulin with a portable pump. *Diabetes care* 3:301-308
86. Dunn FL, Pietri A, Raskin P 1981 Plasma lipid and lipoprotein levels with continuous subcutaneous insulin infusion in type I diabetes mellitus. *Annals of internal medicine* 95:426-431
87. Blackett PR, Holcombe JH, Alaupovic P, Fesmire JD 1986 Plasma lipids and apolipoproteins in a 13-year-old boy with diabetic ketoacidosis and extreme hyperlipidemia. *The American journal of the medical sciences* 291:342-346
88. Weidman SW, Ragland JB, Fisher JN, Jr., Kitabchi AE, Sabesin SM 1982 Effects of insulin on plasma lipoproteins in diabetic ketoacidosis: evidence for a change in high density lipoprotein composition during treatment. *Journal of lipid research* 23:171-182
89. Wilson DP, Fesmire JD, Endres RK, Blackett PR 1985 Increased levels of HDL-cholesterol and apolipoprotein A-I after intensified insulin therapy for diabetes. *Southern medical journal* 78:636-638
90. Katz M, Laffel L 2015 Mortality in type 1 diabetes in the current era: two steps forward, one step backward. *Jama* 313:35-36
91. Orchard TJ, Secrest AM, Miller RG, Costacou T 2010 In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. *Diabetologia* 53:2312-2319
92. Van Waarde WM, Odink RJ, Rouwe C, Stellaard F, Westers M, Vonk RJ, Sauer PJ, Verkade HJ 2001 Postprandial chylomicron clearance rate in late teenagers with diabetes mellitus type 1. *Pediatric research* 50:611-617
93. Mangat R, Su JW, Lambert JE, Clandinin MT, Wang Y, Uwiera RR, Forbes JM, Vine DF, Cooper ME, Mamo JC, Proctor SD 2011 Increased risk of cardiovascular disease in Type 1 diabetes: arterial exposure to remnant lipoproteins leads to enhanced deposition of cholesterol and binding to glycated extracellular matrix proteoglycans. *Diabetic medicine : a journal of the British Diabetic Association* 28:61-72
94. Lewis GF, O'Meara NM, Cabana VG, Blackman JD, Pugh WL, Druetzel AF, Lukens JR, Getz GS, Polonsky KS 1991 Postprandial triglyceride response in type 1 (insulin-dependent) diabetes mellitus is not altered by short-term deterioration in glycaemic control or level of postprandial insulin replacement. *Diabetologia* 34:253-259
95. Goldberg IJ, Bornfeldt KE 2013 Lipids and the endothelium: bidirectional interactions. *Current atherosclerosis reports* 15:365
96. Ooi EM, Barrett PH, Chan DC, Watts GF 2008 Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. *Clinical science* 114:611-624
97. Caron S, Verrijken A, Mertens I, Samanez CH, Mautino G, Haas JT, Duran-Sandoval D, Prawitt J, Francque S, Vallez E, Muhr-Tailleux A, Berard I, Kuipers F, Kuivenhoven JA, Biddinger SB, Taskinen MR, Van Gaal L, Staels B 2011 Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. *Arteriosclerosis, thrombosis, and vascular biology* 31:513-519
98. Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, Dong HH 2004 Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. *The Journal of clinical investigation* 114:1493-1503
99. Blackett P, Sarale DC, Fesmire J, Harmon J, Weech P, Alaupovic P 1988 Plasma apolipoprotein C-III levels in children with type I diabetes. *Southern medical journal* 81:469-473
100. al Muhtaseb N, al Yousuf A, Bajaj JS 1992 Apolipoprotein A-I, A-II, B, C-II, and C-III in children with insulin-dependent

diabetes mellitus. *Pediatrics* 89:936-941

101. Krishnan S, Copeland KC, Bright BC, Gardner AW, Blackett PR, Fields DA 2011 Impact of type 1 diabetes and body weight status on cardiovascular risk factors in adolescent children. *Journal of clinical hypertension* 13:351-356

102. Klein RL, McHenry MB, Lok KH, Hunter SJ, Le NA, Jenkins AJ, Zheng D, Semler A, Page G, Brown WV, Lyons TJ, Garvey WT, Group DER 2005 Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort. *Journal of diabetes and its complications* 19:18-25

103. Jenkins AJ, Yu J, Alaupovic P, Basu A, Klein RL, Lopes-Virella M, Baker NL, Hunt KJ, Lackland DT, Garvey WT, Lyons TJ, Group DER 2013 Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. *Journal of diabetes and its complications* 27:447-453

104. Yu JY, Lyons TJ 2013 Modified Lipoproteins in Diabetic Retinopathy: A Local Action in the Retina. *Journal of clinical & experimental ophthalmology* 4

105. Agarwal AK, Garg A 2003 Congenital generalized lipodystrophy: significance of

triglyceride biosynthetic pathways. *Trends in endocrinology and metabolism*: TEM 14:214-221

106. Garg A 2011 Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. *The Journal of clinical endocrinology and metabolism* 96:3313-3325

107. Beltrand J, Lahlou N, Le Charpentier T, Sebag G, Leka S, Polak M, Tubiana-Rufi N, Lacombe D, de Kerdanet M, Huet F, Robert JJ, Chevenne D, Gressens P, Levy-Marchal C 2010 Resistance to leptin-replacement therapy in Berardinelli-Seip congenital lipodystrophy: an immunological origin. *European journal of endocrinology / European Federation of Endocrine Societies* 162:1083-1091

108. Duntas LH 2002 Thyroid disease and lipids. *Thyroid : official journal of the American Thyroid Association* 12:287-293

109. Catli G, Abaci A, Buyukgebiz A, Bober E 2014 Subclinical hypothyroidism in childhood and adolescence. *Journal of pediatric endocrinology & metabolism : JPEM* 27:1049-1057

110. Rudling M, Norstedt G, Olivecrona H, Reihner E, Gustafsson JA, Angelin B 1992 Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. *Proceedings of the National Academy of Sciences of the United States of America* 89:6983-6987

111. Bengtsson BA, Abs R, Bennmarker H, Monson JP, Feldt-Rasmussen U, Hernberg-Stahl E, Westberg B, Wilton P, Wuster C 1999 The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults.

KIMS Study Group and the KIMS International Board. *The Journal of clinical endocrinology and metabolism* 84:3929-3935

112. Angelin B, Rudling M 1994 Growth hormone and hepatic lipoprotein metabolism. *Current opinion in lipidology* 5:160-165

113. Elam MB, Wilcox HG, Solomon SS, Heimberg M 1992 In vivo growth hormone treatment stimulates secretion of very low density lipoprotein by the isolated perfused rat liver. *Endocrinology* 131:2717-2722

114. Cali AM, Caprio S 2009 Ectopic fat deposition and the metabolic syndrome in obese children and adolescents. *Hormone research* 71 Suppl 1:2-7

115. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP 2004 Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. *Gastroenterology* 126:586-597

116. Clark PJ, Thompson AJ, Vock DM, Kratz LE, Tolun AA, Muir AJ, McHutchison JG, Subramanian M, Millington DM, Kelley RI, Patel K 2012 Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. *Hepatology* 56:49-56

117. Domitrovich AM, Felmler DJ, Siddiqui A 2005 Hepatitis C virus nonstructural proteins inhibit apolipoprotein B100 secretion. *The Journal of biological chemistry* 280:39802-39808

118. Sever S, Weinstein DA, Wolfsdorf JL, Gedik R, Schaefer EJ 2012 Glycogen storage disease type Ia: linkage of glucose, glycogen, lactic acid, triglyceride, and uric acid metabolism. *Journal of clinical lipidology* 6:596-600

119. Fernandes J, Alaupovic P, Wit JM 1989 Gastric drip feeding in patients with glycogen storage disease type I: its effects on growth and plasma lipids and apolipoproteins. *Pediatric research* 25:327-331

120. Shah KK, O'Dell SD 2013 Effect of dietary interventions in the maintenance of normoglycaemia in glycogen storage disease type 1a: a systematic review and meta-analysis. *Journal of human nutrition and dietetics : the official journal of the British Dietetic Association* 26:329-339

121. Kronenberg F 2005 Dyslipidemia and nephrotic syndrome: recent advances. *Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation* 15:195-203

122. de Sain-van der Velden MG, Kaysen GA, Barrett HA, Stellaard F, Gadellaa MM, Voorbij HA, Reijngoud DJ, Rabelink TJ 1998 Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis. *Kidney international* 53:994-1001

123. Attman PO, Alaupovic P 1990 Pathogenesis of hyperlipidemia in the nephrotic syndrome. *American journal of nephrology* 10 Suppl 1:69-75

124. Saland JM, Ginsberg HN 2007 Lipoprotein metabolism in chronic renal insufficiency. *Pediatric nephrology* 22:1095-1112

125. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C 1993 The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. *The Journal of clinical endocrinology and metabolism* 76:1423-1427
126. Riddler SA, Li X, Chu H, Kingsley LA, Dobs A, Evans R, Palella F, Visscher B, Chmiel JS, Sharrett A 2007 Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. *HIV medicine* 8:280-287
127. Beaumont JL, Berard M, Antonucci M, Delplanque B, Vranckx R 1977 Inhibition of lipoprotein lipase activity by a monoclonal immunoglobulin in autoimmune hyperlipidemia. *Atherosclerosis* 26:67-77
128. Nozaki S, Ito Y, Nakagawa T, Yamashita S, Sasaki J, Matsuzawa Y 1997 Autoimmune hyperlipidemia with inhibitory monoclonal antibodies against low density lipoprotein binding to fibroblasts in a case with multiple myeloma. *Internal medicine* 36:920-925
129. Karafin MS, Humphrey RL, Detrick B 2014 Evaluation of monoclonal and oligoclonal gammopathies in a pediatric population in a major urban center. *American journal of clinical pathology* 141:482-487
130. Sholter DE, Armstrong PW 2000 Adverse effects of corticosteroids on the cardiovascular system. *The Canadian journal of cardiology* 16:505-511
131. Schroeder LL, Tang X, Wasko MC, Bili A 2014 Glucocorticoid use is associated with increase in HDL and no change in other lipids in rheumatoid arthritis patients. *Rheumatology international*
132. Bhojwani D, Darbandi R, Pei D, Ramsey LB, Chemaitilly W, Sandlund JT, Cheng C, Pui CH, Relling MV, Jeha S, Metzger ML 2014 Severe hypertriglyceridaemia during therapy for childhood acute lymphoblastic leukaemia. *European journal of cancer* 50:2685-2694
133. Duvillard L, Dautin G, Florentin E, Petit JM, Gamber P, Verges B 2010 Changes in apolipoprotein B100-containing lipoprotein metabolism due to an estrogen plus progestin oral contraceptive: a stable isotope kinetic study. *The Journal of clinical endocrinology and metabolism* 95:2140-2146
134. Guazzelli CA, Lindsey PC, de Araujo FF, Barbieri M, Petta CA, Aldrich JM 2005 Evaluation of lipid profile in adolescents during long-term use of combined oral hormonal contraceptives. *Contraception* 71:118-121
135. Beasley A, Estes C, Guerrero J, Westhoff C 2012 The effect of obesity and low-dose oral contraceptives on carbohydrate and lipid metabolism. *Contraception* 85:446-452
136. Chasan-Taber L, Stampfer MJ 1998 Epidemiology of oral contraceptives and cardiovascular disease. *Annals of internal medicine* 128:467-477
137. Zane LT, Leyden WA, Marqueling AL, Manos MM 2006 A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. *Archives of dermatology* 142:1016-1022
138. McCarter TL, Chen YK 1992 Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy. *The American journal of gastroenterology* 87:1855-1858
139. Standeven AM, Thacher SM, Yuan YD, Escobar M, Vuligonda V, Beard RL, Chandraratna RA 2001 Retinoid X receptor agonist elevation of serum triglycerides in rats by potentiation of retinoic acid receptor agonist induction or by action as single agents. *Biochemical pharmacology* 62:1501-1509
140. Freemantle SJ, Spinella MJ, Dmitrovsky E 2003 Retinoids in cancer therapy and chemoprevention: promise meets resistance. *Oncogene* 22:7305-7315
141. Kuster GM, Drexel H, Bleisch JA, Rentsch K, Pei P, Binswanger U, Amann FW 1994 Relation of cyclosporine blood levels to adverse effects on lipoproteins. *Transplantation* 57:1479-1483
142. Jankowska I, Czubkowski P, Socha P, Wierzbicka A, Teisseyre M, Teisseyre J, Pawlowska J 2012 Lipid metabolism and oxidative stress in children after liver transplantation treated with sirolimus. *Pediatric transplantation* 16:901-906
143. Ballantyne CM, Podet EJ, Patsch WP, Harati Y, Appel V, Gotto AM, Jr., Young JB 1989 Effects of cyclosporine therapy on plasma lipoprotein levels. *Jama* 262:53-56
144. Wissing KM, Unger P, Ghisda L, Broeders N, Berkenboom G, Carpentier Y, Abramowicz D 2006 Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. *Transplantation* 82:771-778
145. Vaziri ND, Liang K, Azad H 2000 Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions. *The Journal of pharmacology and experimental therapeutics* 294:778-783
146. Piloya T, Bakeera-Kitaka S, Kekitiinwa A, Kamya MR 2012 Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study. *Journal of the International AIDS Society* 15:17427
147. Tsiodras S, Mantzoros C, Hammer S, Samore M 2000 Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. *Archives of internal medicine* 160:2050-2056
148. Jones R, Sawleshwarkar S, Michailidis C, Jackson A, Mandalia S, Stebbing J, Bower M, Nelson M, Gazzard BG, Moyle GJ 2005 Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. *HIV medicine* 6:396-402
149. Crouse JR, 3rd 1987 Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. *The*

American journal of medicine 83:243-248

150. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr., Roccella EJ, National Heart L, Blood Institute Joint National Committee on Prevention DE, Treatment of High Blood P, National High Blood Pressure Education Program Coordinating C 2003 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *Jama* 289:2560-2572

151. National High Blood Pressure Education Program Working Group on High Blood Pressure in C, Adolescents 2004 The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics* 114:555-576

152. Libowitz MR, Nurmi EL. The burden of antipsychotic-induced weight gain and metabolic syndrome in children. *Frontiers in Psychiatry*. 2021 Mar 12;12:623681.

153. Takahashi H, Ono M, Hyogo H, Tsuji C, Kitajima Y, Ono N, Eguchi T, Fujimoto K, Chayama K, Saibara T, Anzai K, Eguchi Y 2015 Biphasic effect of alcohol intake on the development of fatty liver disease. *Journal of gastroenterology*

154. Pacifico L, Chiesa C, Anania C, De Merulis A, Osborn JF, Romaggioli S, Gaudio E 2014 Nonalcoholic fatty liver disease and the heart in children and adolescents. *World journal of gastroenterology : WJG* 20:9055-9071

155. Richardson L, Paulis WD, van Middelkoop M, Koes BW 2013 An overview of national clinical guidelines for the management of childhood obesity in primary care. *Preventive medicine* 57:448-455

156. Savoye M, Shaw M, Dziura J, Tamborlane WV, Rose P, Guandalini C, Goldberg-Gell R, Burgert TS, Cali AM, Weiss R, Caprio S 2007 Effects of a weight management program on body composition and metabolic parameters in overweight children: a randomized controlled trial. *Jama* 297:2697-2704

157. Sunil B, Foster C, Wilson DP, Ashraf AP. Novel therapeutic targets and agents for pediatric dyslipidemia. *Therapeutic Advances in Endocrinology and Metabolism*. 2021 Nov;12:20420188211058323.

158. Park ZH, Juska A, Dyakov D, Patel RV 2014 Statin-associated incident diabetes: a literature review. *The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists* 29:317-334

159. De Ferranti SD, Steinberger J, Ameduri R, Baker A, Gooding H, Kelly AS, Mietus-Snyder M, Mitsnefes MM, Peterson AL, St-Pierre J, Urbina EM. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association. *Circulation*. 2019 Mar 26;139(13):e603-34.

160. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E 2000 VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial.

*Circulation* 102:1886-1892

161. Triglyceride Coronary Disease Genetics C, Emerging Risk Factors C, Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J 2010 Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. *Lancet* 375:1634-1639

162. Wheeler KA, West RJ, Lloyd JK, Barley J 1985 Double blind trial of bezafibrate in familial hypercholesterolaemia. *Archives of disease in childhood* 60:34-37

163. Colletti RB, Neufeld EJ, Roff NK, McAuliffe TL, Baker AL, Newburger JW 1993 Niacin treatment of hypercholesterolemia in children. *Pediatrics* 92:78-82

164. Bays H 2006 Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. *The American journal of cardiology* 98:71i-76i

165. Harris WS 1997 n-3 fatty acids and serum lipoproteins: human studies. *The American journal of clinical nutrition* 65:1645S-1654S

166. Park Y, Harris WS 2009 Dose-response of n-3 polyunsaturated fatty acids on lipid profile and tolerability in mildly hypertriglyceridemic subjects. *Journal of medicinal food* 12:803-808

168. Harris WS, Windsor SL, Dujovne CA 1991 Effects of four doses of n-3 fatty acids given to hyperlipidemic patients for six months. *Journal of the American College of Nutrition* 10:220-227

169. Chahal N, Manthot C, Wong H, McCrindle BW 2014 Effectiveness of Omega-3 Polysaturated Fatty Acids (Fish Oil) Supplementation for Treating Hypertriglyceridemia in Children and Adolescents. *Clinical pediatrics* 53:645-651

170. Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN 2012 Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). *Journal of clinical lipidology* 6:565-572

171. Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, Kling D, Davidson MH 2014 Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. *Journal of clinical lipidology* 8:94-106

172. Harris WS 1996 n-3 fatty acids and lipoproteins: comparison of results from human and animal studies. *Lipids* 31:243-252

173. Hypertriglyceridemia in Children and Adolescents. 2023 Feb 22. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Singer F,

---

Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): [MDText.com](http://MDText.com), Inc.; 2000-. PMID: 27809432.

174. Goldberg IJ. Hypertriglyceridemia: impact and treatment. Endocrinology and metabolism clinics of North America. 2009 Mar 1;38(1):137-49.